EI
SYRS

EAM Investors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

EAM Investors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-84,002
Closed -$654K – 345
2023
Q4 		$654K Buy
+84,002
New +$288K 0.12% 203

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

EAM Investors's SYRS Position: Q1 2024 in Review

EAM Investors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2024, closing a stake of 84,002 shares — an estimated $654K sold.

EAM Investors first reported a position in SYRS in Q4 2023 and held it in 1 quarter. The position peaked at $654K in Q4 2023. 75 funds tracked by Wall St. Rank hold SYRS as of Q1 2024.

  • EAM Investors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 84,002 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $654K.
  • EAM Investors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • EAM Investors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $654K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.